Moussa Mohamad, Abou Chakra Mohamad, Moussa Yasmin
Department of Urology, Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon.
Department of Urology, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
Intractable Rare Dis Res. 2020 Feb;9(1):10-13. doi: 10.5582/irdr.2019.01130.
Peyronie's disease (PD) is a connective tissue disorder of the penis characterized by fibrosis and plaque formation within the tunica albuginea. PD is characterized by painful penile curvature that impairs sexual intercourse. Stem cell therapy is one of the recent non-invasive treatment options for patients with PD and it has promising results. Stem cells are undifferentiated cells that are capable of self-renewal and differentiation, promoting the repair of tissues via their immunomodulatory and anti-inflammatory action. Adipose-derived stem cells (ADSC) are used most widely due to their abundant tissue source and ease of isolation. Multiple studies have indicated the efficacy of stem cell therapy as a potential treatment for fibrotic diseases. Clearly, ADSCs may represent a way to treat and prevent PD in both rat and human models. Further clinical studies are needed to confirm the efficacy of stem cell therapy for PD in humans.
佩罗尼氏病（PD）是一种阴茎的结缔组织疾病，其特征是白膜内出现纤维化和斑块形成。佩罗尼氏病的特点是阴茎疼痛性弯曲，会妨碍性交。干细胞疗法是近期针对佩罗尼氏病患者的非侵入性治疗选择之一，且已取得了有前景的结果。干细胞是未分化的细胞，能够自我更新和分化，通过其免疫调节和抗炎作用促进组织修复。脂肪来源干细胞（ADSC）因其丰富的组织来源和易于分离而被最广泛使用。多项研究表明干细胞疗法作为纤维化疾病的潜在治疗方法具有有效性。显然，脂肪来源干细胞可能是在大鼠和人类模型中治疗和预防佩罗尼氏病的一种方法。需要进一步的临床研究来证实干细胞疗法对人类佩罗尼氏病的疗效。
